financetom
Business
financetom
/
Business
/
S&P revises outlook on Boeing to 'negative'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
S&P revises outlook on Boeing to 'negative'
Apr 25, 2024 8:11 AM

April 25 (Reuters) - Ratings agency S&P Global Ratings

said on Thursday it has revised its outlook on planemaker Boeing ( BA )

to "negative" from "stable".

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Basel Medical Group Reiterates in Regulatory Filing Underlying Business Strength Following Continued Volatility in Shares
Basel Medical Group Reiterates in Regulatory Filing Underlying Business Strength Following Continued Volatility in Shares
Jun 4, 2025
05:46 AM EDT, 06/04/2025 (MT Newswires) -- Basel Medical Group's ( BMGL ) shares were trading down more than 12% in premarket activity Wednesday, heading for another day of volatile price moves despite the company making statements regarding its fundamental underlying strength. On Tuesday, the company issued a Form 6-K regulatory filing, drawing attention to a press statement from May...
Sagimet Biosciences Says Acne Vulgaris Treatment Meets Phase 3 Trial Primary, Secondary Endpoints
Sagimet Biosciences Says Acne Vulgaris Treatment Meets Phase 3 Trial Primary, Secondary Endpoints
Jun 4, 2025
05:43 AM EDT, 06/04/2025 (MT Newswires) -- Sagimet Biosciences ( SGMT ) said Wednesday that denifanstat met all primary and secondary endpoints in a phase 3 clinical trial to treat moderate to severe acne vulgaris. The trial was conducted by the company's license partner Ascletis Bioscience in China. Denifanstat was generally well-tolerated, the company said. After 12 weeks of once-daily...
Autoliv raises dividend, reiterates 2025 guidance
Autoliv raises dividend, reiterates 2025 guidance
Jun 4, 2025
STOCKHOLM, June 4 (Reuters) - Swedish Autoliv , the world's biggest maker of airbags and seatbelts, on Wednesday reiterated its outlook for 2025 and said it would raise its dividend for the third quarter to $0.85 per share from $0.70 in the second quarter. Autoliv ( ALV ) said in a statement it would tweak its target leverage ratio to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved